Mar 4, 2026 03:03AM JPMorgan Starts Protera Therapeutics (TARA) at Overweight

Mar 4, 2026 03:03AM JPMorgan Starts Protara Therapeutics (TARA) at Overweight

Feb 23, 2026 05:06PM Protara reports 68% response rate for bladder cancer therapy TARA-002

Jan 12, 2026 07:01AM Protara Therapeutics outlines 2026 milestones for cancer trials

Jan 7, 2026 03:46AM Piper Sandler Starts Protera Therapeutics (TARA) at Overweight

Nov 20, 2025 06:41AM H.C. Wainwright Reiterates Buy Rating on Protera Therapeutics (TARA)

Nov 20, 2025 06:02AM Oppenheimer Reiterates Outperform Rating on Protera Therapeutics (TARA)

Nov 10, 2025 05:02PM Protara Therapeutics, Inc. (TARA) Tops Q3 EPS by 7c

Oct 9, 2025 06:43AM H.C. Wainwright Reiterates Buy Rating on Protera Therapeutics (TARA)

Oct 6, 2025 06:50AM H.C. Wainwright Reiterates Buy Rating on Protera Therapeutics (TARA)

Aug 11, 2025 08:59AM Protara Therapeutics, Inc. (TARA) Tops Q2 EPS by 5c

Jun 30, 2025 08:10AM Protara Therapeutics (TARA) Announces Addition to the Russell 3000 Index

Jun 2, 2025 04:04PM Protara Therapeutics (TARA) names William Conkling as Chief Commercial Officer

May 8, 2025 05:19PM Protara Therapeutics, Inc. (TARA) Tops Q1 EPS by 18c

Apr 28, 2025 12:32PM Protara Therapeutics (TARA) Announces Positive Interim Results Demonstrating Durable Responses in the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC

Apr 15, 2025 04:14PM Protara Therapeutics (TARA) Appoints Leonardo Viana Nicacio as Chief Medical Officer

Apr 10, 2025 04:07PM Protara Therapeutics (TARA) to present phase 2 analysis of TARA-002 trial

Mar 19, 2025 08:03AM Protara Therapeutics (TARA) Announces Encore Presentation of Results from THRIVE-1 Prospective Observational Study Evaluating the Prevalence of Choline Deficiency and Liver Injury in Patients Dependen

Mar 14, 2025 06:06AM Cantor Fitzgerald Starts Protera Therapeutics (TARA) at Overweight

Mar 6, 2025 07:26AM H.C. Wainwright Reiterates Buy Rating on Protera Therapeutics (TARA)

Mar 5, 2025 08:02AM Protara Therapeutics, Inc. (TARA) Tops Q4 EPS by 11c

Dec 9, 2024 04:01PM Protara Therapeutics (TARA) Announces Proposed Public Offering

Dec 6, 2024 06:49AM H.C. Wainwright Reiterates Buy Rating on Protera Therapeutics (TARA), 'TARA-002 holds an attractive position in the treatment of NMIBC'

Dec 5, 2024 11:08AM TD Cowen Reiterates Buy Rating on Protera Therapeutics (TARA)

Dec 5, 2024 07:01AM Protara Therapeutics (TARA) Reports Positive Results from the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002

Nov 12, 2024 08:10AM Protara Therapeutics, Inc. (TARA) Tops Q3 EPS by 2c

Oct 21, 2024 08:02AM Protara Therapeutics (TARA) Granted FDA Fast Track Designation for Intravenous Choline Chloride for Patients Receiving Parenteral Support

Sep 12, 2024 06:18AM Oppenheimer Reiterates Outperform Rating on Protera Therapeutics (TARA)

Sep 9, 2024 02:22PM TD Cowen Reiterates Buy Rating on Protera Therapeutics (TARA)

Sep 9, 2024 08:05AM Protara Therapeutics (TARA) Announces Results from THRIVE-1

Aug 6, 2024 02:01PM TD Cowen Reiterates Buy Rating on Protera Therapeutics (TARA)

Aug 6, 2024 09:46AM Protara Therapeutics, Inc. (TARA) Tops Q2 EPS by 29c